Core Viewpoint - The implementation of the "Special Regulations on the Supervision and Management of Traditional Chinese Medicine Production" marks a significant upgrade in industry regulation, focusing on quality compliance and high-quality development in the traditional Chinese medicine sector [4][6]. Regulatory Changes - The new regulations establish legal requirements for the production of traditional Chinese medicine (TCM) products, including decoction pieces, formula granules, and injection preparations, addressing long-standing compliance gaps [9][10]. - The regulations specifically prohibit practices such as outsourcing, re-labeling, and production beyond approved scopes, which have contributed to quality issues in TCM products [10][11]. Industry Impact - The regulations are expected to accelerate industry restructuring, with a clear differentiation among segments like decoction pieces, formula granules, and injection preparations, where compliance and cost management will become core challenges for companies [7][14]. - Companies that achieve full compliance and upgrade their operations will likely dominate the market, while those lacking production capabilities and quality control will be eliminated [14][15]. Compliance Requirements - The regulations impose stricter production thresholds for formula granules, requiring companies to self-manufacture and maintain complete production capabilities, including quality traceability and risk management [11][12]. - For injection preparations, the regulations clarify the responsibilities of the marketing authorization holder (MAH) and set stringent requirements for production processes and quality control [12]. Innovation and Transformation - The regulations encourage companies to adopt modern technologies for quality management and production processes, promoting automation and digitalization in the TCM industry [14][15]. - The shift towards innovation-driven growth is expected to enhance industry concentration and extend the value chain of TCM, with 2026 anticipated to be a pivotal year for digital transformation [15].
中药生产监管新规正式施行
21世纪经济报道·2026-03-05 13:42